Abstract

PurposeTo examine the relationship between optical coherence tomography (OCT) images and clinical course in eyes with branch retinal vein occlusion (BRVO) treated with intravitreal ranibizumab injection (IVR).DesignProspective cohort study.ParticipantsThirty eyes of 30 patients with BRVO treated with IVR.MethodsAll patients received 1 initial IVR followed by repeated injections in the pro re nata (PRN) regimen. Correlations between logarithm of minimum angle of resolution best-corrected visual acuity (logMAR BCVA) or number of IVRs after 12 months and OCT parameters including the external limiting membrane (ELM), ellipsoid zone (EZ), interdigitation zone (IZ), and photoreceptor outer segment (PROS) length at first resolution of macular edema (ME) were assessed. Resolution of ME was defined as central foveal thickness <300 μm and the absence of subretinal fluid. OCT parameters influencing BCVA and number of IVRs were evaluated using multivariate analysis. Correlations between nonperfusion areas (NPAs) and thinning areas and changes in retinal thickness of BRVO-affected areas were assessed.ResultsOf the 30 patients, 27 completed this study and were included in the statistical analyses. The mean logMAR BCVA at 3, 6, and 12 months was 0.16 ± 0.19, 0.09 ± 0.20, and 0.07 ± 0.20, respectively, which improved significantly from baseline at each visit (p < 0.0001, respectively), while the mean number of IVRs at 12 months was 3.9 ± 2.2. The mean number of IVRs for the first resolution of ME was 1.6 ± 0.8. Eyes with ELM and EZ defects at the points of first resolution of ME were correlated with a significantly lower BCVA at 12 months compared with eyes with preserved ELMs and EZs (p = 0.035, p = 0.002, respectively). However, eyes with IZ defects at the points of first resolution of ME were not correlated with a significantly lower BCVA at 12 months compared with eyes with preserved IZs (p = 0.160). Defects in the EZ at the points of first resolution of ME significantly affected the number of IVRs at 12 months (p = 0.042), although the ELM and IZ did not. PROS length at the points of first resolution of ME was significantly correlated with BCVA and number of IVRs at 12 months (p = 0.006, p = 0.0008, respectively). In multivariate analysis, PROS length at the points of first resolution of ME had the most significant effect on BCVA and number of IVRs (p = 0.013, p = 0.012, respectively). NPA size on fluorescein angiography and thinning area on OCT within the macular area showed a significant correlation (p = 0.003, r = 0.971). The retinal thickness of ischemic BRVO-affected areas was significantly less than that of control areas at 10, 11, and 12 months (p = 0.001, p = 0.005, p = 0.003, respectively).ConclusionWe showed that the 1+PRN regimen may be a useful therapy for ME due to BRVO. In addition, PROS length at points of first resolution of ME appears to be a good indicator of BCVA and number of IVRs in BRVO patients.

Highlights

  • Branch retinal vein occlusion (BRVO) is a retinal vascular disease and cause of visual loss due to macular edema (ME) and retinal ischemia

  • Eyes with external limiting membrane (ELM) and ellipsoid zone (EZ) defects at the points of first resolution of ME were correlated with a significantly lower best-corrected visual acuity (BCVA) at 12 months compared with eyes with preserved ELMs and EZs (p = 0.035, p = 0.002, respectively)

  • Defects in the EZ at the points of first resolution of ME significantly affected the number of intravitreal ranibizumab (IVR) at 12 months (p = 0.042), the ELM and interdigitation zone (IZ) did not

Read more

Summary

Introduction

Branch retinal vein occlusion (BRVO) is a retinal vascular disease and cause of visual loss due to macular edema (ME) and retinal ischemia. The Branch Vein Occlusion Study (BVOS) reported that grid laser photocoagulation increased visual acuity in patients with ME due to BRVO[1]. In 2009, the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study showed that intravitreal triamcinolone administration resulted in similar visual improvement but with high rates of intraocular pressure elevation[2]. Anti-vascular endothelial growth factor (VEGF) has been used for the treatment of ME due to RVO, with greater increases in visual acuity compared with laser photocoagulation [3,4,5,6,7,8]. Anti-VEGF treatment resulted in marked improvement in visual acuity in patients with BRVO. Miwa et al have reported that one initial intravitreal ranibizumab injection (IVR) and 3 monthly IVR regimens achieved similar functional outcomes at 12 months[9]. Loading-dose ranibizumab injections in the treatment of ME due to BRVO may be unnecessary

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call